Oriola Corporation insider information 28 August 2019 at 3:30 p.m. Oriola and Orion renew their distribution agreement in Finland Oriola and Orion have signed a new distribution agreement on 28 August 2019. According to the agreement, Oriola continues to provide warehousing and distribution services for Orion’s human and veterinary pharmaceuticals in Finland. The new agreement is effective from 1 May 2020. The close cooperation of the two Finnish companies will continue to ensure quality and timely logistics of pharmaceuticals to support the healthcare in Finland. “The demanding and strongly regulated pharmaceutical logistics is at the core of Oriola’s competence. We have developed our operations to respond to the constantly growing and changing pharmaceutical market. We want to secure good medicine availability in Finland,” says President and CEO Robert Andersson. Orion is a Finnish pharmaceutical company developing, manufacturing and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients. The wholesale value of Orion’s human pharmaceuticals in Finland was approximately 270 million euros and market share of the Finnish pharmaceutical market approximately 11% in 2018*. In addition to the product categories covered by the new agreement, Orion manufactures non-pharmaceutical products with a wholesale value of approximately 48 million euros in 2018*. *Source: IQVIA Oriola Corporation Robert Andersson President and CEO Further information: Robert Andersson President and CEO Tel. +358 10 429 2109 Email: robert.andersson@oriola.com Tuula Lehto Group Communications Director Tel. +358 40 5885 343 Email: tuula.lehto@oriola.com Distribution: Nasdaq Helsinki Ltd. Key media Released by: Oriola Corporation Corporate Communications Orionintie 5 02200 Espoo www.oriola.com